These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11736962)

  • 1. Bone marrow aplasia after pipobroman: an immune-mediated mechanism?
    Triffet A; Straetmans N; Ferrant A
    Br J Haematol; 2001 Dec; 115(3):713-4. PubMed ID: 11736962
    [No Abstract]   [Full Text] [Related]  

  • 2. Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.
    Bouscary D; Jondeau K; Viguié F; Zompi S; Fontenay-Roupie M; Quarre MC; Vassilief D; Dreyfus F; Casadevall N
    Leuk Lymphoma; 1999 May; 33(5-6):607-11. PubMed ID: 10342591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is hydroxyurea leukemogenic in essential thrombocythemia?
    Tefferi A
    Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
    [No Abstract]   [Full Text] [Related]  

  • 5. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
    Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
    Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
    Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
    Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset.
    Orlandi E; Bernasconi P; Boni M; Calatroni S; Lazzarino M
    Ann Hematol; 2005 Feb; 84(2):127-8. PubMed ID: 15378276
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
    Passamonti F; Lazzarino M
    Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F; Cazzola M
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy of pipobroman in the treatment of essential thrombocythemia].
    Bauters F; Jouet JP; Simon M; Pollet JP; Fenaux P; Walter MP
    Presse Med; 1988 Jan; 17(2):81. PubMed ID: 2964031
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of factitious aplastic anemia.
    Bright R; Eisendrath S; Damon L
    Int J Psychiatry Med; 2001; 31(4):433-41. PubMed ID: 11949741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
    Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
    Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multiples squamous cell carcinomas during treatment with pipobroman].
    Tchen T; Durlach A; Bernard P; Grange F
    Ann Dermatol Venereol; 2007; 134(6-7):570-1. PubMed ID: 17657187
    [No Abstract]   [Full Text] [Related]  

  • 14. Pipobroman therapy of essential thrombocythemia.
    Mazzucconi MG; Francesconi M; Chistolini A; Falcione E; Ferrari A; Tirindelli MC; Mandelli F
    Scand J Haematol; 1986 Oct; 37(4):306-9. PubMed ID: 3787181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin for sulphasalazine-induced aplastic anaemia in a patient with early rheumatoid arthritis.
    Nurmohamed MT; Soesan M; van Oers MH; Dijkmans BA; van Soesbergen RM
    Rheumatology (Oxford); 2000 Dec; 39(12):1431-3. PubMed ID: 11136894
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
    Morris EB; Kasow K; Reiss U; Ellison D; Broniscer A
    J Neurooncol; 2009 Jan; 91(2):237-9. PubMed ID: 18818880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia.
    Shvidel L; Sigler E; Haran M; Klepfish A; Duek A; Berrebi A; Shtalrid M
    Leukemia; 2007 Sep; 21(9):2071-2. PubMed ID: 17611572
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment with cyclosporine of thymoma-related aplastic anemia.
    Gaglia A; Bobota A; Pectasides E; Kosmas C; Papaxoinis G; Pectasides D
    Anticancer Res; 2007; 27(4C):3025-8. PubMed ID: 17695491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis.
    Tefferi A; Cerquozzi S; Liaw J
    Am J Hematol; 2016 Feb; 91(2):E6-7. PubMed ID: 26587685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.